WO2026028149 - , AND COMPOSITIONS AND METHODS RELATING THERETO
National phase entry is expected:
Publication Number
WO/2026/028149
Publication Date
05.02.2026
International Application No.
PCT/IB2025/057809
International Filing Date
31.07.2025
Title **
[English]
, AND COMPOSITIONS AND METHODS RELATING THERETO
[French]
ET COMPOSITIONS ET PROCÉDÉS ASSOCIÉS
Applicants **
INCISIVE GENETICS, INC.
THE UNIVERSITY OF BRITISH COLUMBIA
Inventors
CAPRON, Arnaud
CARON, Nicholas
HILL, Austin
LEAVITT, Blair
WAGNER, Pamela
YI, Yuyin
Priority Data
63/678,331
01.08.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CIPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3595 | |
| EPO | Filing, Examination, Granting | 22800 | |
| Japan | Filing, Examination, Granting | 2578 | |
| South Korea | Filing, Examination, Granting | 2963 | |
| USA | Filing, Examination, Granting | 13840 |
Total:
45,776
Contact Us
Abstract[English]
The present disclosure provides gRNAs for editing SERPINA1 and combinations of such gRNAs, nucleic acids encoding such gRNAs, vectors comprising such nucleic acids, RNPs comprising such gRNAs and endonucleases, pharmaceutical compositions comprising any of the foregoing, and kits comprising any of the foregoing. The present disclosure further provides methods related to such gRNAs, including methods of manufacturing, methods of effecting SERPINA1 gene editing, and methods of preventing, treating, or ameliorating a symptom of a target disease, disorder, or condition such as A1ATD.[French]
La présente divulgation concerne des ARNg pour l'édition de SERPINA1 et des associations de tels ARNg, des acides nucléiques codant de tels ARNg, des vecteurs comprenant de tels acides nucléiques, des RNP comprenant de tels ARNg et des endonucléases, des compositions pharmaceutiques comprenant l'un quelconque de ceux-ci et des kits comprenant l'un quelconque de ceux-ci. La présente divulgation concerne également des procédés liés à de tels ARNg, notamment des procédés de fabrication, des procédés permettant d'effectuer une édition génétique de SERPINA1 et des procédés permettant de prévenir, traiter ou atténuer un symptôme d'une maladie, d'un trouble ou d'une pathologie cible tels que A1ATD.